Low impact
Bristol Myers Squibb raises 2026 earnings guidance after beating quarterly results on new drug sales including Opdivo, offsetting declining legacy portfolio revenue.
Finnhub07/30, 06:14 PM
Related assets
Coming up for BMY
Explore next
Latest BMY news
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.
Finnhub08/04, 12:17 AM
Finnhub08/03, 10:50 PM